These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 39408205)

  • 1. Peanut Allergy in Children-Is Prevention Better than Cure?
    Krejner-Bienias A; Łyżwa K; Krupa-Łaska A; Zielińska J; Kulus M; Grzela K
    Nutrients; 2024 Sep; 16(19):. PubMed ID: 39408205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peanut (
    Casale TB; Irani AM
    Expert Rev Clin Immunol; 2023 Mar; 19(3):253-265. PubMed ID: 36524617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
    Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peanut Allergy: New Advances and Ongoing Controversies.
    Abrams EM; Chan ES; Sicherer S
    Pediatrics; 2020 May; 145(5):. PubMed ID: 32303583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peanut allergy and oral immunotherapy.
    Lee TH; Chan JKC; Lau PC; Luk WP; Fung LH
    Hong Kong Med J; 2019 Jun; 25(3):228-234. PubMed ID: 31178442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food allergy: Update on prevention and tolerance.
    Du Toit G; Sampson HA; Plaut M; Burks AW; Akdis CA; Lack G
    J Allergy Clin Immunol; 2018 Jan; 141(1):30-40. PubMed ID: 29191680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current state and advances in desensitization for peanut allergy in pediatric age.
    Foti Randazzese S; Panasiti I; Caminiti L; Catamerò F; Landi M; De Filippo M; Votto M; Olcese R; Favuzza F; Giovannini M; Barberi S
    Pediatr Allergy Immunol; 2024 Apr; 35(4):e14127. PubMed ID: 38646959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Trend in Immunotherapy for Peanut Allergy.
    Joo Chan C; Richardo T; Lim RLH
    Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current opinion and review on peanut oral immunotherapy.
    Deol S; Bird JA
    Hum Vaccin Immunother; 2014; 10(10):3017-21. PubMed ID: 25483680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peanut Allergy: Changes in Dogma and Past, Present, and Future Directions.
    Boudreau-Romano S; Qamar N
    Pediatr Ann; 2018 Jul; 47(7):e300-e304. PubMed ID: 30001445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose immunotherapy in very young children to treat peanut allergy.
    Vickery BP
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1251-1253. PubMed ID: 27599211
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on peanut allergy: Prevention and immunotherapy.
    Cook QS; Kim EH
    Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy approaches for peanut allergy.
    Kim EH; Patel C; Burks AW
    Expert Rev Clin Immunol; 2020 Feb; 16(2):167-174. PubMed ID: 31928251
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
    Anagnostou K; Islam S; King Y; Foley L; Pasea L; Bond S; Palmer C; Deighton J; Ewan P; Clark A
    Lancet; 2014 Apr; 383(9925):1297-1304. PubMed ID: 24485709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific oral tolerance induction in childhood.
    Peters RL; Dang TD; Allen KJ
    Pediatr Allergy Immunol; 2016 Dec; 27(8):784-794. PubMed ID: 27496561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
    Chu DK; Wood RA; French S; Fiocchi A; Jordana M; Waserman S; Brożek JL; Schünemann HJ
    Lancet; 2019 Jun; 393(10187):2222-2232. PubMed ID: 31030987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy.
    Remington BC; Krone T; Kim EH; Bird JA; Green TD; Lack G; Fleischer DM; Koppelman SJ
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):488-493.e2. PubMed ID: 31442495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.
    Schneider LC; Rachid R; LeBovidge J; Blood E; Mittal M; Umetsu DT
    J Allergy Clin Immunol; 2013 Dec; 132(6):1368-74. PubMed ID: 24176117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.